pentoxifylline has been researched along with Necrotizing Enterocolitis in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited." | 9.30 | Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. ( Batty, KT; Doherty, DA; Hibbert, J; Manning, L; Page-Sharp, M; Patole, S; Salman, S; Simmer, K; Strunk, T, 2019) |
| "To assess the effect of intravenous pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity in neonates with suspected or confirmed sepsis." | 8.91 | Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2015) |
| "The primary objectives were to assess the effect on mortality and the safety of intravenous pentoxifylline as an adjunct to antibiotic therapy in neonates with suspected or confirmed sepsis and NEC." | 8.87 | Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2011) |
| "Pentoxifylline (PTX) is a candidate adjuvant medication for the treatment of sepsis and necrotizing enterocolitis in preterm infants." | 7.96 | Intravenous pentoxifylline is well tolerated in critically ill preterm infants with sepsis or necrotizing enterocolitis. ( Berger, A; Kempf, K; Schüller, SS; Strunk, T; Unterasinger, L, 2020) |
| "Mortality and morbidity due to neonatal sepsis and necrotising enterocolitis (NEC) remain high despite the use of potent antimicrobial agents." | 7.01 | Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates. ( Haque, KN; Pammi, M, 2023) |
| " Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited." | 5.30 | Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. ( Batty, KT; Doherty, DA; Hibbert, J; Manning, L; Page-Sharp, M; Patole, S; Salman, S; Simmer, K; Strunk, T, 2019) |
| "To assess the effect of intravenous pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity in neonates with suspected or confirmed sepsis." | 4.91 | Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2015) |
| "The primary objectives were to assess the effect on mortality and the safety of intravenous pentoxifylline as an adjunct to antibiotic therapy in neonates with suspected or confirmed sepsis and NEC." | 4.87 | Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. ( Haque, KN; Pammi, M, 2011) |
| "Pentoxifylline (PTX) is a candidate adjuvant medication for the treatment of sepsis and necrotizing enterocolitis in preterm infants." | 3.96 | Intravenous pentoxifylline is well tolerated in critically ill preterm infants with sepsis or necrotizing enterocolitis. ( Berger, A; Kempf, K; Schüller, SS; Strunk, T; Unterasinger, L, 2020) |
| "Mortality and morbidity due to neonatal sepsis and necrotising enterocolitis (NEC) remain high despite the use of potent antimicrobial agents." | 3.01 | Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates. ( Haque, KN; Pammi, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pammi, M | 4 |
| Haque, KN | 3 |
| Kurul, S | 1 |
| Allegaert, K | 1 |
| Flint, RB | 1 |
| Taal, HR | 1 |
| Schüller, SS | 1 |
| Kempf, K | 1 |
| Unterasinger, L | 1 |
| Strunk, T | 2 |
| Berger, A | 1 |
| Salman, S | 1 |
| Hibbert, J | 1 |
| Page-Sharp, M | 1 |
| Manning, L | 1 |
| Simmer, K | 2 |
| Doherty, DA | 1 |
| Patole, S | 2 |
| Batty, KT | 1 |
| Harpavat, S | 1 |
| Gilger, M | 1 |
| Erdener, D | 1 |
| Bakirtas, F | 1 |
| Alkanat, M | 1 |
| Mutaf, I | 1 |
| Habif, S | 1 |
| Bayindir, O | 1 |
| Travadi, J | 1 |
| Charles, A | 1 |
| Dvorak, B | 1 |
| Doherty, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline Dose Optimization in Preterm Neonatal Late Onset Sepsis[NCT04152980] | Phase 3 | 40 participants (Anticipated) | Interventional | 2020-01-12 | Recruiting | ||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
4 reviews available for pentoxifylline and Necrotizing Enterocolitis
| Article | Year |
|---|---|
Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates.
Topics: Anti-Bacterial Agents; Enterocolitis, Necrotizing; Humans; Immunoglobulin M; Immunoglobulins, Intrav | 2023 |
Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Infections; Chemotherapy, Adjuvant; Enter | 2015 |
Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Infections; Chemotherapy, Adjuvant; Enter | 2011 |
Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Infections; Chemotherapy, Adjuvant; Enter | 2011 |
Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Infections; Chemotherapy, Adjuvant; Enter | 2011 |
Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Infections; Chemotherapy, Adjuvant; Enter | 2011 |
Novel treatments for NEC: keeping IBD in mind.
Topics: Enterocolitis, Necrotizing; Glucocorticoids; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2012 |
1 trial available for pentoxifylline and Necrotizing Enterocolitis
| Article | Year |
|---|---|
Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes.
Topics: Administration, Intravenous; Body Weight; Drug Therapy, Combination; Enterocolitis, Necrotizing; Fem | 2019 |
4 other studies available for pentoxifylline and Necrotizing Enterocolitis
| Article | Year |
|---|---|
"How can a drug to treat claudication in adults save preterm newborns?"
Topics: Critical Illness; Enterocolitis, Necrotizing; Humans; Infant; Infant, Newborn; Infant, Premature; Pe | 2020 |
Intravenous pentoxifylline is well tolerated in critically ill preterm infants with sepsis or necrotizing enterocolitis.
Topics: Critical Illness; Drug Administration Schedule; Enterocolitis, Necrotizing; Female; Humans; Infant, | 2020 |
Pentoxifylline does not prevent hypoxia/reoxygenation-induced necrotizing enterocolitis. An experimental study.
Topics: Animals; Animals, Newborn; Enterocolitis, Necrotizing; Glutathione Peroxidase; Glutathione Reductase | 2004 |
Pentoxifylline reduces the incidence and severity of necrotizing enterocolitis in a neonatal rat model.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Enterocolitis, Necrotizing; Free Radical Scavenge | 2006 |